Vertex Pharmaceuticals Incorporated (VRTX) Earnings Call Analysis

NASDAQ · Healthcare · Biotechnology

20/25

Growth 5 Margin 4 Expansion 4 Platform 2 Financial 5

latest quarter score

Earnings Reports

20
Vertex (VRTX) Q2 2026: Non-CF Revenue Surges 150% as Renal and Pain Launches Scale
August 04, 2026
21
Vertex (VRTX) Q3 2025: Genavix Prescriptions Surge to 300,000 as Renal Pipeline Accelerates
June 16, 2026
24
Vertex Pharmaceuticals (VRTX) Q4 2025: Non-CF Portfolio Set to Exceed $500M, Anchoring Multi-Vertical Expansion
June 15, 2026
22
Vertex (VRTX) Q1 2026: Non-CF Portfolio Drives 25% of Growth as Renal Franchise Accelerates
May 05, 2026
24
Vertex (VRTX) Q2 2025: Genavix Prescriptions Top 110,000 as Commercial Diversification Accelerates
August 04, 2025
23
Vertex (VRTX) Q1 2025: Genavix Fills 25,000 Prescriptions as Commercial Diversification Accelerates
June 30, 2025

Browse all companies